Last Updated on December 31, 2023 by The Health Master
Panacea Biotec on Tuesday said that it has entered into an agreement to sell its formulation business in India and Nepal to Mankind Pharma for Rs. 1908 crore.
In FY21, the domestic business assets generated a turnover of Rs 219.85 crore, which is 35.19% of the company’s revenue on a consolidated basis. Panacea reported revenues of Rs 625 crore in FY21.
Panacea said it expects to complete the transaction by the end of this year.
Panacea domestic business gets most of its revenues from therapeutic segments such as organ transplantation, diabetes, pain, cough, and cold, and gastroenterology.
The company top selling brands are:
- Pangraf (tacrolimus),
- Alphadol (alfacalcidol),
- Cilamin (penicillamine)
- Livoluk Fibre (lactulose in combination with ispaghula)
These brands were ranked number one, whereas Glizid (Gliclazide + Metformin), Mycept (Mycophenolate Mofetil) were amongst the top 5 brands in their respective markets.
Panacea has been struggling with high debt. The company has a net debt of Rs 984 crore on a consolidated basis with a debt equity ratio of 4.53.
Pharma distributor among 3 held for illegal sale of Anesthetic drugs
IPC flags safety alert against most common Drug Ibuprofen – NSAID
Govt invites third round of applications under PLI Scheme for domestic API manufacturing
USFDA issues 3 observations to Granules Pharmaceuticals Inc
Blaine Labs recalled of RevitaDerm Wound Care Gel Due to this reason
NPPA seeks clarification on license status of clotrimazole 1% mouth paint
China to strengthen anti-monopoly efforts in Pharma industry
USFDA gives nod to Granules Pharma for potassium chloride for oral solution
Govt Job: For M.Pharm, M.Sc at CDSCO – Central Government | Pay upto Rs. 92,300 pm
Latest Notifications regarding Pharmaceuticals
